메뉴 건너뛰기




Volumn 49, Issue 11, 2014, Pages 1352-1359

An update on allogeneic hematopoietic progenitor cell transplantation for myeloproliferative neoplasms in the era of tyrosine kinase inhibitors

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; JANUS KINASE 2 INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; JAK2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

EID: 84909983020     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.176     Document Type: Review
Times cited : (8)

References (57)
  • 2
    • 69249104612 scopus 로고    scopus 로고
    • The 2008 World Health Organization classification system for myeloproliferative neoplasms: Order out of chaos
    • Tefferi A, Thiele J, Vardiman JW. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos. Cancer 2009; 115: 3842-3847.
    • (2009) Cancer , vol.115 , pp. 3842-3847
    • Tefferi, A.1    Thiele, J.2    Vardiman, J.W.3
  • 3
    • 0015694748 scopus 로고
    • Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining
    • Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290-293.
    • (1973) Nature , vol.243 , pp. 290-293
    • Rowley, J.D.1
  • 4
    • 77957088676 scopus 로고    scopus 로고
    • Stem cell transplant for chronic myeloid leukemia in the imatinib era [review]
    • Radich J. Stem cell transplant for chronic myeloid leukemia in the imatinib era [review]. Semin Hematol 2010; 47: 354-361.
    • (2010) Semin Hematol , vol.47 , pp. 354-361
    • Radich, J.1
  • 5
    • 34249664406 scopus 로고    scopus 로고
    • Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia
    • Hehlmann R, Berger U, Pfirrmann M, Heimpel H, Hochhaus A, Hasford J et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007; 109: 4686-4692.
    • (2007) Blood , vol.109 , pp. 4686-4692
    • Hehlmann, R.1    Berger, U.2    Pfirrmann, M.3    Heimpel, H.4    Hochhaus, A.5    Hasford, J.6
  • 6
    • 77949767505 scopus 로고    scopus 로고
    • International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib
    • Deininger M, O'Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP et al. International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib. ASH Annu Meet Abstr 2009; 114: 1126.
    • (2009) ASH Annu Meet Abstr , vol.114 , pp. 1126
    • Deininger, M.1    O'Brien, S.G.2    Guilhot, F.3    Goldman, J.M.4    Hochhaus, A.5    Hughes, T.P.6
  • 7
    • 0032480589 scopus 로고    scopus 로고
    • Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
    • Gratwohl A, Hermans J, Goldman JM, Arcese W, Carreras E, Devergie A et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087-1092.
    • (1998) Lancet , vol.352 , pp. 1087-1092
    • Gratwohl, A.1    Hermans, J.2    Goldman, J.M.3    Arcese, W.4    Carreras, E.5    Devergie, A.6
  • 8
    • 33646017748 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: Transplant activity, long-term data and current results An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)
    • Gratwohl A, Brand R, Apperley J, Crawley C, Ruutu T, Corradini P et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513-521.
    • (2006) Haematologica , vol.91 , pp. 513-521
    • Gratwohl, A.1    Brand, R.2    Apperley, J.3    Crawley, C.4    Ruutu, T.5    Corradini, P.6
  • 9
    • 70350341896 scopus 로고    scopus 로고
    • The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia - A report from the German Registry covering the period from 1998 to 2004
    • Bacher U, Klyuchnikov E, Zabelina T, Ottinger H, Beelen DW, Schrezenmeier H et al. The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia - a report from the German Registry covering the period from 1998 to 2004. Ann Hematol 2009; 88: 1237-1247.
    • (2009) Ann Hematol , vol.88 , pp. 1237-1247
    • Bacher, U.1    Klyuchnikov, E.2    Zabelina, T.3    Ottinger, H.4    Beelen, D.W.5    Schrezenmeier, H.6
  • 10
    • 34247863611 scopus 로고    scopus 로고
    • Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    • Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007; 137: 461-467.
    • (2007) Br J Haematol , vol.137 , pp. 461-467
    • Giralt, S.A.1    Arora, M.2    Goldman, J.M.3    Lee, S.J.4    Maziarz, R.T.5    McCarthy, P.L.6
  • 11
    • 54049146732 scopus 로고    scopus 로고
    • Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia
    • Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008; 112: 3500-3507.
    • (2008) Blood , vol.112 , pp. 3500-3507
    • Lee, S.J.1    Kukreja, M.2    Wang, T.3    Giralt, S.A.4    Szer, J.5    Arora, M.6
  • 12
    • 77950391550 scopus 로고    scopus 로고
    • Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: Evaluation of its impact within a subgroup of the randomized German CML Study IV
    • Saussele S, Lauseker M, Gratwohl A, Beelen DW, Bunjes D, Schwerdtfeger R et al. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV. Blood 2010; 115: 1880-1885.
    • (2010) Blood , vol.115 , pp. 1880-1885
    • Saussele, S.1    Lauseker, M.2    Gratwohl, A.3    Beelen, D.W.4    Bunjes, D.5    Schwerdtfeger, R.6
  • 13
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
    • (2001) Science , vol.293 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Rao, P.N.6
  • 14
    • 79953689908 scopus 로고    scopus 로고
    • Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
    • Jabbour E, Cortes J, Santos FPS, Jones D, O'Brien S, Rondon G et al. Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations. Blood 2011; 117: 3641-3647.
    • (2011) Blood , vol.117 , pp. 3641-3647
    • Jabbour, E.1    Cortes, J.2    Santos, F.P.S.3    Jones, D.4    O'Brien, S.5    Rondon, G.6
  • 15
    • 84860841611 scopus 로고    scopus 로고
    • Initial findings from the PACE Trial: A pivotal phase. 2. Study of Ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation
    • Cortes JE, Kim D-W, Pinilla-Ibarz J, Le Coutre PD, Chuah C, Nicolini FE et al. Initial findings from the PACE Trial: a pivotal phase. 2. study of Ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Annu Meet Abstr 2011; 118: 109.
    • (2011) ASH Annu Meet Abstr , vol.118 , pp. 109
    • Cortes, J.E.1    Kim, D.-W.2    Pinilla-Ibarz, J.3    Le Coutre, P.D.4    Chuah, C.5    Nicolini, F.E.6
  • 16
    • 80755185510 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias
    • Nicolini FE, Basak GW, Soverini S, Martinelli G, Mauro MJ, Müller MC et al. Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias. Blood 2011; 118: 5697-5700.
    • (2011) Blood , vol.118 , pp. 5697-5700
    • Nicolini, F.E.1    Basak, G.W.2    Soverini, S.3    Martinelli, G.4    Mauro, M.J.5    Müller, M.C.6
  • 17
    • 33747156914 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
    • Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure. Blood 2006; 108: 1421-1423.
    • (2006) Blood , vol.108 , pp. 1421-1423
    • Jabbour, E.1    Cortes, J.2    Kantarjian, H.M.3    Giralt, S.4    Jones, D.5    Jones, R.6
  • 18
    • 84909982783 scopus 로고    scopus 로고
    • Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia in accelerated phase: A single center experience in China after a 9-year follow-up
    • Jiang Q, Xu L-P, Liu D-H, Liu K, Chen S-S, Jiang B et al. Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia in accelerated phase: a single center experience in China after a 9-year follow-up. ASH Annu Meet Abstr 2010; 116: 2347.
    • (2010) ASH Annu Meet Abstr , vol.116 , pp. 2347
    • Jiang, Q.1    Xu, L.-P.2    Liu, D.-H.3    Liu, K.4    Chen, S.-S.5    Jiang, B.6
  • 19
    • 84891490008 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation for CML in second chronic phase after blast crisis in the tyrosine kinase inhibitor era
    • Ahmed S, Chiattone A, Jones R, Sphall EJ, Farhan S, Rondon G et al. Allogeneic stem cell transplantation for CML in second chronic phase after blast crisis in the tyrosine kinase inhibitor era. ASH Annu Meet Abstr 2011; 118: 2039-.
    • (2011) ASH Annu Meet Abstr , vol.118 , pp. 2039
    • Ahmed, S.1    Chiattone, A.2    Jones, R.3    Sphall, E.J.4    Farhan, S.5    Rondon, G.6
  • 20
    • 50649111595 scopus 로고    scopus 로고
    • HLA-mismatched/ haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: Improved outcomes in patients in accelerated phase and blast crisis phase
    • Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Huan C, Wei H et al. HLA-mismatched/ haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for chronic myeloid leukemia: improved outcomes in patients in accelerated phase and blast crisis phase. Ann Med 2008; 40: 444-455.
    • (2008) Ann Med , vol.40 , pp. 444-455
    • Xiao-Jun, H.1    Lan-Ping, X.2    Kai-Yan, L.3    Dai-Hong, L.4    Huan, C.5    Wei, H.6
  • 21
    • 84909964922 scopus 로고    scopus 로고
    • Safety and efficacy of haploidentical stem cell transplantation for advanced chronic myeloid leukemia
    • Adekola K, di Stasi A, Ferro R, Ahmed S, de Lima MJG, Oran B et al. Safety and efficacy of haploidentical stem cell transplantation for advanced chronic myeloid leukemia. Biol Blood Marrow Transplant 2014; 20: S213-S214.
    • (2014) Biol Blood Marrow Transplant , vol.20 , pp. S213-S214
    • Adekola, K.1    Di Stasi, A.2    Ferro, R.3    Ahmed, S.4    De Lima, M.J.G.5    Oran, B.6
  • 22
    • 84872970465 scopus 로고    scopus 로고
    • Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management
    • Tefferi A. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management. Am J Hematol 2013; 88: 141-150.
    • (2013) Am J Hematol , vol.88 , pp. 141-150
    • Tefferi, A.1
  • 23
    • 84865174824 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors
    • Gupta V, Hari P, Hoffman R. Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. Blood 2012; 120: 1367-1379.
    • (2012) Blood , vol.120 , pp. 1367-1379
    • Gupta, V.1    Hari, P.2    Hoffman, R.3
  • 25
    • 84875879764 scopus 로고    scopus 로고
    • Ruxolitinib: An oral Janus kinase 1 and Janus kinase. 2. Inhibitor in the management of myelofibrosis
    • Verstovsek S. Ruxolitinib: an oral Janus kinase. 1. and Janus kinase. 2. inhibitor in the management of myelofibrosis. Postgrad Med 2013; 125: 128-135.
    • (2013) Postgrad Med , vol.125 , pp. 128-135
    • Verstovsek, S.1
  • 26
    • 84858668231 scopus 로고    scopus 로고
    • The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation
    • Scott BL, Gooley TA, Sorror ML, Rezvani AR, Linenberger ML, Grim J et al. The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation. Blood 2012; 119: 2657-2664.
    • (2012) Blood , vol.119 , pp. 2657-2664
    • Scott, B.L.1    Gooley, T.A.2    Sorror, M.L.3    Rezvani, A.R.4    Linenberger, M.L.5    Grim, J.6
  • 27
    • 79952087335 scopus 로고    scopus 로고
    • DIPSS plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status
    • Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392-397.
    • (2011) J Clin Oncol , vol.29 , pp. 392-397
    • Gangat, N.1    Caramazza, D.2    Vaidya, R.3    George, G.4    Begna, K.5    Schwager, S.6
  • 28
    • 79953711716 scopus 로고    scopus 로고
    • How i treat myelofibrosis
    • Tefferi A. How I treat myelofibrosis. Blood 2011; 117: 3494-3504.
    • (2011) Blood , vol.117 , pp. 3494-3504
    • Tefferi, A.1
  • 29
    • 77949401992 scopus 로고    scopus 로고
    • Allogeneic hemopoietic SCT for patients with primary myelofibrosis: A predictive transplant score based on transfusion requirement, spleen size and donor type
    • Bacigalupo A, Soraru M, Dominietto A, Pozzi S, Geroldi S, Van Lint MT et al. Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplant 2010; 45: 458-463.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 458-463
    • Bacigalupo, A.1    Soraru, M.2    Dominietto, A.3    Pozzi, S.4    Geroldi, S.5    Van Lint, M.T.6
  • 30
    • 84859411901 scopus 로고    scopus 로고
    • Management of myelofibrosis
    • Vannucchi AM. Management of myelofibrosis. Hematology 2011; 2011: 222-230.
    • (2011) Hematology , vol.2011 , pp. 222-230
    • Vannucchi, A.M.1
  • 31
    • 78149465870 scopus 로고    scopus 로고
    • The role of allogeneic SCT in primary myelofibrosis: A British Society for Blood and Marrow Transplantation study
    • Stewart WA, Pearce R, Kirkland KE, Bloor A, Thomson K, Apperley J et al. The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study. Bone Marrow Transplant 2010; 45: 1587-1593.
    • (2010) Bone Marrow Transplant , vol.45 , pp. 1587-1593
    • Stewart, W.A.1    Pearce, R.2    Kirkland, K.E.3    Bloor, A.4    Thomson, K.5    Apperley, J.6
  • 33
    • 73949084969 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: A prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation
    • Kroger N, Holler E, Kobbe G, Bornhauser M, Schwerdtfeger R, Baurmann H et al. Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Blood 2009; 114: 5264-5270.
    • (2009) Blood , vol.114 , pp. 5264-5270
    • Kroger, N.1    Holler, E.2    Kobbe, G.3    Bornhauser, M.4    Schwerdtfeger, R.5    Baurmann, H.6
  • 34
    • 84865184403 scopus 로고    scopus 로고
    • Results of Phase II Clinical Trial MPD-RC 101: Allogeneic hematopoietic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis
    • Rondelli D, Goldberg JD, Marchioli R, Isola L, Shore TB, Prchal JT et al. Results of Phase II Clinical Trial MPD-RC 101: allogeneic hematopoietic stem cell transplantation conditioned with fludarabine/melphalan in patients with myelofibrosis. ASH Annu Meet Abstr 2011; 118: 1750.
    • (2011) ASH Annu Meet Abstr , vol.118 , pp. 1750
    • Rondelli, D.1    Goldberg, J.D.2    Marchioli, R.3    Isola, L.4    Shore, T.B.5    Prchal, J.T.6
  • 35
    • 33846880278 scopus 로고    scopus 로고
    • Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis
    • Kröger N, Badbaran A, Holler E, Hahn J, Kobbe G, Bornhäuser M et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 2007; 109: 1316-1321.
    • (2007) Blood , vol.109 , pp. 1316-1321
    • Kröger, N.1    Badbaran, A.2    Holler, E.3    Hahn, J.4    Kobbe, G.5    Bornhäuser, M.6
  • 36
    • 77956302639 scopus 로고    scopus 로고
    • Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis
    • Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572-3581.
    • (2010) Blood , vol.116 , pp. 3572-3581
    • Alchalby, H.1    Badbaran, A.2    Zabelina, T.3    Kobbe, G.4    Hahn, J.5    Wolff, D.6
  • 38
    • 12844284481 scopus 로고    scopus 로고
    • Leukemic transformation in myelofibrosis with myeloid metaplasia: A single-institution experience with
    • Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with. 91. cases. Blood 2005; 105: 973-977.
    • (2005) 91. Cases. Blood , vol.105 , pp. 973-977
    • Mesa, R.A.1    Li, C.Y.2    Ketterling, R.P.3    Schroeder, G.S.4    Knudson, R.A.5    Tefferi, A.6
  • 40
    • 84878225843 scopus 로고    scopus 로고
    • Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms
    • Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013; 121: 2725-2733.
    • (2013) Blood , vol.121 , pp. 2725-2733
    • Kennedy, J.A.1    Atenafu, E.G.2    Messner, H.A.3    Craddock, K.J.4    Brandwein, J.M.5    Lipton, J.H.6
  • 41
    • 79953074952 scopus 로고    scopus 로고
    • Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
    • Bacher U, Haferlach T, Schnittger S, Kreipe H, Kroger N. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia. Br J Haematol 2011; 153: 149-167.
    • (2011) Br J Haematol , vol.153 , pp. 149-167
    • Bacher, U.1    Haferlach, T.2    Schnittger, S.3    Kreipe, H.4    Kroger, N.5
  • 42
    • 84859452133 scopus 로고    scopus 로고
    • Current status of allogeneic HST for chronic myelomonocytic leukemia
    • Cheng H, Kirtani VG, Gergis U. Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplant 2012; 47: 535-541.
    • (2012) Bone Marrow Transplant , vol.47 , pp. 535-541
    • Cheng, H.1    Kirtani, V.G.2    Gergis, U.3
  • 43
    • 41849134682 scopus 로고    scopus 로고
    • Diagnosis and management of chronic myelomonocytic leukemia
    • Onida F, Beran M. Diagnosis and management of chronic myelomonocytic leukemia. Curr Hematol Malign Rep 2008; 3: 31-36.
    • (2008) Curr Hematol Malign Rep , vol.3 , pp. 31-36
    • Onida, F.1    Beran, M.2
  • 44
    • 84861349850 scopus 로고    scopus 로고
    • Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management
    • Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012; 87: 610-619.
    • (2012) Am J Hematol , vol.87 , pp. 610-619
    • Parikh, S.A.1    Tefferi, A.2
  • 45
    • 79952349006 scopus 로고    scopus 로고
    • Cytogenetic risk stratification in chronic myelomonocytic leukemia
    • Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica 2011; 96: 375-383.
    • (2011) Haematologica , vol.96 , pp. 375-383
    • Such, E.1    Cervera, J.2    Costa, D.3    Sole, F.4    Vallespi, T.5    Luno, E.6
  • 46
    • 0036464647 scopus 로고    scopus 로고
    • Prognostic factors and scoring systems in chronic myelomonocytic leukemia: A retrospective analysis of 213 patients
    • Onida F, Kantarjian HM, Smith TL, Ball G, Keating MJ, Estey EH et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood 2002; 99: 840-849.
    • (2002) Blood , vol.99 , pp. 840-849
    • Onida, F.1    Kantarjian, H.M.2    Smith, T.L.3    Ball, G.4    Keating, M.J.5    Estey, E.H.6
  • 47
    • 0036067374 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [Multicenter Study]
    • Kroger N, Zabelina T, Guardiola P, Runde V, Sierra J, Van Biezen A et al. Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT) [Multicenter Study]. Br J Haematol 2002; 118: 67-73
    • (2002) Br J Haematol , vol.118 , pp. 67-73
    • Kroger, N.1    Zabelina, T.2    Guardiola, P.3    Runde, V.4    Sierra, J.5    Van Biezen, A.6
  • 49
    • 84894282273 scopus 로고    scopus 로고
    • Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: The impact of WHO classification and of the conditioning regimen on the transplantation outcome
    • Symeonidis A, van Biezen A, Mufti G, Finke J, Beelen D, Bornhauser M et al. Allogeneic stem cell transplantation in patients with chronic myelomonocytic leukaemia: the impact of WHO classification and of the conditioning regimen on the transplantation outcome. Bone Marrow Transplant 2010; 45 (Suppl 2): S241.
    • (2010) Bone Marrow Transplant , vol.45 , pp. S241
    • Symeonidis, A.1    Van Biezen, A.2    Mufti, G.3    Finke, J.4    Beelen, D.5    Bornhauser, M.6
  • 50
  • 51
    • 79956054105 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: Relapsefree survival is determined by karyotype and comorbidities
    • Eissa H, Gooley TA, Sorror ML, Nguyen F, Scott BL, Doney K et al. Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapsefree survival is determined by karyotype and comorbidities. Biol Blood Marrow Transplant 2011; 17: 908-915.
    • (2011) Biol Blood Marrow Transplant , vol.17 , pp. 908-915
    • Eissa, H.1    Gooley, T.A.2    Sorror, M.L.3    Nguyen, F.4    Scott, B.L.5    Doney, K.6
  • 52
    • 84909942843 scopus 로고    scopus 로고
    • Outcomes in patients with chronic myelomonocytic leukemia: Analysis of 279 patients
    • Borthakur G, Beran M, Liu J, Verma D, Dong XQ, Rondon G et al. Outcomes in patients with chronic myelomonocytic leukemia: analysis of 279 patients. ASH Annu Meet Abstr 2008; 112: 3235.
    • (2008) ASH Annu Meet Abstr , vol.112 , pp. 3235
    • Borthakur, G.1    Beran, M.2    Liu, J.3    Verma, D.4    Dong, X.Q.5    Rondon, G.6
  • 53
    • 20144363192 scopus 로고    scopus 로고
    • Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [article]
    • Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas M, Swanton S et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders [article]. Lancet 2005; 365: 1054-1061.
    • (2005) Lancet , vol.365 , pp. 1054-1061
    • Baxter, E.J.1    Scott, L.M.2    Campbell, P.J.3    East, C.4    Fourouclas, M.5    Swanton, S.6
  • 54
    • 0035120673 scopus 로고    scopus 로고
    • Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia
    • Jurado M, Deeg H, Gooley T, Anasetti C, Chauncey T, Flowers M et al. Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia. Br J Haematol 2001; 112: 392-396.
    • (2001) Br J Haematol , vol.112 , pp. 392-396
    • Jurado, M.1    Deeg, H.2    Gooley, T.3    Anasetti, C.4    Chauncey, T.5    Flowers, M.6
  • 55
    • 0036290026 scopus 로고    scopus 로고
    • Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation
    • Platzbecker U, Gooley T, Anasetti C, Appelbaum FR, Clurman B, Doney K, et al. Curative therapy of advanced essential thrombocythemia or polycythemia vera by hemopoietic stem cell transplantation. Leuk Lymphoma 2002; 43: 1409-1414.
    • (2002) Leuk Lymphoma , vol.43 , pp. 1409-1414
    • Platzbecker, U.1    Gooley, T.2    Anasetti, C.3    Appelbaum, F.R.4    Clurman, B.5    Doney, K.6
  • 56
    • 33847083481 scopus 로고    scopus 로고
    • Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia
    • Kerbauy DM, Gooley TA, Sale GE, Flowers ME, Doney KC, Georges GE et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplant 2007; 13: 355-365.
    • (2007) Biol Blood Marrow Transplant , vol.13 , pp. 355-365
    • Kerbauy, D.M.1    Gooley, T.A.2    Sale, G.E.3    Flowers, M.E.4    Doney, K.C.5    Georges, G.E.6
  • 57
    • 84865198731 scopus 로고    scopus 로고
    • Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia
    • Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M et al. Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. Biol Blood Marrow Transplant 2012; 18: 1446-1454.
    • (2012) Biol Blood Marrow Transplant , vol.18 , pp. 1446-1454
    • Ballen, K.K.1    Woolfrey, A.E.2    Zhu, X.3    Ahn, K.W.4    Wirk, B.5    Arora, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.